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Abstract There is no consensus regarding the deﬁnition
of cardiac syndrome X (CSX). We systematically reviewed
recent literature using a standardized search strategy. We
included 57 articles. A total of 47 studies mentioned a
male/female distribution. A meta-analysis yielded a pooled
proportion of females of 0.56 (n = 1,934 patients, with
95% conﬁdence interval: 0.54–0.59). As much as 9 inclu-
sion criteria and 43 exclusion criteria were found in the 57
articles. Applying these criteria to a population with nor-
mal coronary angiograms and treated in 1 year at a general
hospital, the attributable CSX incidence varied between 3
and 11%. The many inclusion and exclusion criteria result
in a wide range of deﬁnitions of CSX and these have large
effects on the incidence. This shows the need for a gen-
erally accepted deﬁnition of CSX.
Keywords Cardiac syndrome X  Microvascular angina 
Angina pectoris and normal coronary arteries
Introduction
The syndrome of angina pectoris with a normal coronary
arteriogram, often termed cardiac syndrome X (CSX), is an
important clinical entity [65]. About 20% of patients with
anginal chest pain have normal coronary angiograms
(CAG). Some physicians regard this as sufﬁcient to diag-
nose CSX, the so-called broad diagnosis of CSX [65, 66].
However, the cause of CSX is not conclusively established
and its deﬁnition is controversial. For example, a subgroup
of these patients have objective signs of ischaemia, such as
the classic downsloping ST-segment depression on exer-
cise testing and/or a reversible defect detected by myo-
cardial single-photon emission computed tomography
(SPECT). Consequently, other authorities consider that
CSX is discounted by a positive result from any diagnostic
test for ischaemia, especially SPECT; and there is also the
view that CSX might best be relabelled as one of several
causes of microvascular dysfunction [37]. Furthermore,
there are various exclusion criteria, such as hypertension
and diabetes, that may or may not be used to discount the
diagnosis of CSX. Finally, in overviews and textbooks it is
often stated that (pre-menopausal) women are especially
prone to developing cardiac syndrome X. In fact, some
authors exclusively study female patient populations, but
there is considerable variation in the proportion of women
in other studies of CSX patients.
The present paper is a review to determine the gender
and main deﬁnitions for CSX in the recent literature and
also the effects of different deﬁnitions upon the attributable
CSX incidence. To study this latter aspect we examined
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Methods
CSX deﬁnitions
The PubMed database was used to identify papers in which
criteria and deﬁnitions for CSX are described. Our search
consisted of ‘(cardiac syndrome x[tiab]) NOT (case
reports[pt] OR comment[pt] OR review[pt])’, with limits
set to English language, humans, and publication date
between June 2003 and July 2008. We limited our search
strategy to cardiac syndrome X and excluded metabolic
syndrome X and tako-tsubo cardiomyopathy [6, 24, 42].
This search yielded 112 references. Conference
abstracts, pediatric papers, and ‘epublications ahead of
print’ were excluded. Of 83 articles the full text was
retrieved for further analysis. Articles were independently
surveyed by two authors (IV and GT) and reviewed with
regard to their used deﬁnitions of CSX. The survey left 57
studies for this review.
Impact of CSX deﬁnition upon CSX incidence
All the CAGs made in 2003 in a general hospital (Spaarne
Hospital Hoofddorp, The Netherlands) were collected. An
extensive search was made to obtain the clinical history,
physical examination, routine laboratory tests, and echo-
cardiography results for all patients with CAGs stated to be
completely normal. All CAGs were independently evalu-
ated by two experienced observers (AK and DO).
Only patients with original angiograms and sufﬁcient
clinical data were included in the present study.
Results
CSX deﬁnitions
The 57 papers selected for determining the main deﬁnitions
of CSX covered a total of 2,375 patients. A normal coro-
nary angiogram was used in the majority of the studies.
However, in a few studies minimal coronary artery disease,
like atheromatous plaque without critical obstructions, is
included as ‘‘normal coronary angiogram’’ [18, 22, 56]. A
few studies state minimal coronary artery disease in the
exclusion criteria [1]. But in the majority of the studies
there was no statement regarding minimal artery disease.
Only few studies speciﬁed the interpretation of the normal
coronary angiograms, like revision of the CAG ﬁlms,
blinded observation, or interpretation by more reviewers.
Table 1liststhenineCSXdeﬁnitions,andhenceinclusion
criteria, obtained from our review of the 57 studies.
In more detail:
• Out of the 57 studies 42 required positive exercise
electrocardiograms for the diagnosis of CSX. The
general criterion, when given, for a positive exercise
stress test result was uniform ST depression C1 mm.
Only one study considered stress-induced angina with-
out signiﬁcant ST depression to be positive for
ischaemia [15].
• As much as 11 studies regarded positive myocardial
perfusion images to be good alternatives to a positive
result from exercise testing.
• As much as 18 studies considered effort-induced angina
pectoris as an inclusion criterion.
• Four studies deﬁned CSX simply as angina pectoris and
normal CAG, the so-called broad diagnosis of CSX.
Table 1 Inclusion criteria for CSX
Inclusion criteria for CSX Number
of studies
Angina pectoris 18
Positive exercise stress test
Normal coronary arteries
Effort induced angina pectoris 17
Positive exercise stress test
Normal coronary arteries
Angina pectoris 11
Positive exercise stress test OR positive SPECT
Normal coronary arteries
Angina pectoris 4
Normal coronary arteries
Angina pectoris 4
Positive exercise stress test AND positive SPECT
Normal coronary arteries
Angina pectoris 1
Positive exercise stress test
No signiﬁcant CAD on CAG
Effort induced AP 1
Positive exercise stress test
Normal coronary arteries AND prolonged coronary
ﬂow on CAG
Angina pectoris 1
Positive exercise stress test
Normal coronary arteries AND reduced LVEF on echo
Angina pectoris 1
Positive SPECT
Normal coronary arteries
CSX cardiac syndrome X; AP angina pectoris; CAG coronary
angiogram; SPECT single photon emission tomography; LVEF left
ventricular ejection fraction
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123Table 2 lists no less than 43 exclusion criteria for CSX.
The most frequently used exclusion criteria are valvular
heart disease, diabetes mellitus, left ventricular hypertro-
phy, hypertension, and cardiomyopathy.
In overviews and textbooks it is often stated that (pre-
menopausal) women are especially prone to develop car-
diac syndrome X.
In Table 3 data of individual studies are presented.
Table 2 Exclusion criteria included studies
Exclusion criteria used in the studies for present
review
N studies of 57
total
Valvular heart disease 33
Diabetes mellitus 32
Left ventricular hypertrophy 26
Hypertension 24
Cardiomyopathy (non speciﬁed) 23
Renal failure 22
History of myocardial infarction 15
LV dysfunction 14
Coronary spasm 13
Hepatic dysfunction 12
Arrhytmias 9
Inﬂammatory disease 9
Dyslipidaemia 8
Left bundel branch block 8
Cardiac disease (non speciﬁed) 7
Gastro Intestinal disorder 7
Systemic disease (non speciﬁed) 6
Smoking 6
Thyroid dysfunction 5
Obesitas 5
Non-cardiac chest pain 5
Condunction disorder (incl LBTB) 5 (13)
Hypertrophic CMP (total CMP) 5 (23)
Congestive CMP (total CMP) 5 (23)
Dilated CMP (CMP total) 4 (23)
Alcoholism 4
Metabolic syndrome 4
Dysphagia/oesophagitis 3
Malignancy 3
LVEF\40% 2
Psychiatric ilness 2
Auto immune disease 2
Estrogen replacement therapy 2
PTCA/CABG in history 2
Ectasia on CAG 2
Bridging on CAG 2
Claudicatio intermittens 2
Heart failure (non specﬁed) (total) 1 (17)
Myocarditis 1
Congenital heart disease 1
Aortic wall diseases 1
Anaemia 1
Thrombocytopenia 1
Table 3 Included studies of CSX patients
Included study
of CSX patients
Year n Female
(%)
Mean
age (Y)
Lee [41] 2008 21 81 55
Timurkaynak [61] 2008 79 54 50
Cemin [11] 2008 11 100 59
Zorc-Pleskovic [66] 2008 31 100 55
Lanza [38] 2008 18 61 58
Altun [2] 2007 9 77 49
Cotrim [12] 2008 91 48 51
Asbury [5] 2008 64 100 58
Demir [18] 2008 17 41 57
Grabczewska [23] 2007 53 57 55
Li [44] 2007 36 100 NA
Okyay [48] 2007 32 66 53
Dabek [15] 2007 34 65 57
Yildiz [64] 2007 10 79 49
Kayikcioglu [33] 2007 30 60 46
Mao [45] 2007 51 78 21
Dabek [14] 2007 36 65 57
Vermeltfoort [63] 2007 20 75 55
Galiuto [21] 2007 17 53 55
Alroy [1] 2007 42 100 52
Huang [29] 2007 12 60 63
Guzik [28] 2007 43 65 44
Gur [26] 2007 23 70 49
Gur [27] 2007 23 NA NA
Sgueglia [59] 2007 30 73 61
Russell [55] 2007 24 89 54
Sen [56] 2007 203 58 53
Shmilovich [60] 2007 17 71 58
de Vries [17] 2006 42 26 58
Nam [47] 2006 52 NA NA
Eskandarian [19] 2006 40 73 46
Cay [10] 2006 126 62 53
Jadhav [30] 2006 52 100 56
Czepczynski [13] 2006 68 63 45
Leu [43] 2006 92 21 64
Lanza [40] 2005 10 59 70
Cay [9] 2005 80 52 51
On [49] 2005 36 53 36
Guo [25] 2005 22 68 48
Masci [46] 2005 41 NA 53
Senen [57] 2005 21 48 56
Pasqui [51] 2005 30 60 54
Sestito [58] 2005 30 73 60
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123In 53 out of the total of 57 included studies the female/
male distribution of the study population was mentioned.
Six studies were focussed upon female patients with CSX.
These studies were excluded for the pooling of the pro-
portion of women in the study populations. Ultimately 47
studies with a total of 1,934 patients could be used for the
meta-analysis.
The proportion of women in the 47 studies of CSX
patients varied considerably ranging from 0.21 to 1.0, with
a pooled estimate of 0.56 (95% conﬁdence interval: 0.54–
0.59), see also Fig. 1. Hence, there is a signiﬁcantly higher
proportion of woman compared to males in the group of
patients with CSX.
CSX incidence
As much as 567 CAGs were performed in 1 year at a
general hospital. Figure 2 is a ﬂowchart showing how we
analysed the available information. The main stages are:
• Original CAGs or clinical data could not be found for
eight patients, leaving 559 cases for analysis.
• Out of the available 559 CAGs 78 (14%) were
considered as absolutely normal.
• Excluding 13 cases with no angina pectoris as indica-
tion for CAG, and another 5 with an acute coronary
syndrome, resulted in an incidence of 60 (11%) CSX
patients according to the broad diagnosis of CSX
(angina pectoris and normal coronary arteries) [17, 23,
54, 65, 66].
• Another 15 cases were excluded owing to the lack of
exercise stress tests or myocardial perfusion imaging
preceding the CAG.
• Of the remaining 45 cases, 28 were included owing to
positive results for ischaemia from exercise tests or
SPECT.
• Finally, a much stricter deﬁnition of CSX was obtained
by using the main exclusion criteria shown in the
second-to-last stage in Fig. 2. This strict deﬁnition
resulted in an attributable CSX incidence of 18 (3%)
patients.
Discussion
CSX deﬁnitions and incidences
The present review of recent archival literature demon-
strates that there is a wide range of deﬁnitions of CSX.
This wide range of deﬁnitions has a large effect on the
attributable incidence of CSX, as has been shown by an
analysis of all available CAGs and other clinical data for
a population of patients treated in 1 year at a general
hospital.
Fig. 1 Plot of proportion of women of individual studies, including
95% conﬁdence intervals
Table 3 continued
Included study
of CSX patients
Year n Female
(%)
Mean
age (Y)
De Candia [16] 2005 21 57 55
Valeriani [62] 2005 16 50 60
Cavusoglu [8] 2005 31 45 52
Kolasinska-Kloch [36] 2004 42 52 46
Kolasilska-Kloch [35] 2004 25 36 49
Altun [3] 2004 8 75 46
Asbury [4] 2004 100 100 61
Fabian [20] 2004 40 40 55
Lanza [39] 2004 55 50 57
Qian [54] 2004 126 47 53
Osamichi [50] 2004 24 71 58
Gorgulu [22] 2003 18 44 51
Pizzi [53] 2004 NA NA 59
Kidawa [34] 2003 50 64 49
NA not available
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123Generally, it is stated that patients with chest pain and
normal coronary arteriogram may represent 10–20% of
those undergoing coronary arteriography because of clini-
cal suspicion of angina [65]. This is in broad agreement
with our analysis results that 11% of patients had a normal
CAG. The rather low incidence of normal CAG can be the
result of the use of rather strict criteria for a normal CAG
including a consensus reading by two independent readers
of the CAG’s.
It is generally accepted (e.g. in authoritative textbooks)
that the majority of the CSX patients are women [32, 65].
Some authors have even suggested that CSX is a women’s
disease. However, our review has found a pooled relative
female frequency of 56% in a population of more than
1,900 CSX patients. Thus, our data do not support the
assumption that CSX is a women’s disease, since 44% of
the population was male. Potential pathophysiological
explanations, such as estrogen depletion, which are based
upon the female gender, apply only to a part of the CSX
patients [31].
Inclusion and exclusion criteria
The literature survey showed that the inclusion and
exclusion criteria varied. This was especially the case for
the exclusion criteria.
The deﬁnition of ‘normal coronary arteries’ was par-
ticularly unclear. Most studies did not deﬁne a normal
CAG, and some included patients with coronary artery
disease (CAD) ranging from minimal to stenoses up to
50% of luminal diameter. Obviously, normal coronary
arteries are the cornerstone of the diagnosis of CSX.
Hence, there should be no doubt regarding the use of this
inclusion criterion for studies of CSX patients. Future
studies of CSX patients should make a clear description
regarding the evaluation and results of the CAG studies of
the coronary artery anatomy.
The so-called broad diagnosis for CSX, a combination
of 2 inclusion criteria (angina pectoris and normal coronary
arteries) was used only in four studies (7%).
Most studies used a combination of three inclusion cri-
teria, namely (effort induced) angina pectoris, positive
exercise test result, and a normal CAG. This deﬁnition was
used in 46 out of 57 studies (81%). The use of this addi-
tional inclusion criterion resulted in a decrease of the
incidence of CSX to 7% in our population. The deﬁnition
of a positive exercise stress test appears to be more stan-
dardized than the deﬁnition of a normal CAG. Most pub-
lications used a ST depression C1 mm as a positive
exercise stress test: only 12 out of the 57 studies did not
deﬁne a positive stress test.
The use of speciﬁc exclusion criteria ranged from 2 to
58% of the selected studies of CSX patients, often
depending on the main objectives of the studies, for
example the use of thrombocytopenia as an exclusion cri-
terion in a study investigating the mean platelet volume [9].
The most frequently mentioned exclusion criteria are
valvular heart disease, diabetes mellitus, left ventricular
hypertrophy, hypertension, and cardiomyopathy. Endothe-
lial dysfunction has been assessed both in patients with
diabetes mellitus and hypertension with normal CAG, and
in patients with CSX without diabetes or hypertension.
Interestingly, coronary ﬂow reserve may be reversible in
speciﬁc patient groups, e.g. in patients with hypertrophy
after anti-hypertensive therapy [52]. However, we note that
most international studies consider diabetes mellitus and
hypertension to be exclusion criteria for CSX, thereby
considering these patients as a separate group.
The existence of such a long list of exclusion criteria in
the selection process of CSX patients illustrates the lack of
agreement between the different research groups regarding
number of lost clinical data
n=8
Patients with abnormal CAG
n=481
indication for CAG:
valvular heart disease n=2
arrhytmia n=3
cardiomyopathy n=3
indication for CAG:
troponin release n=5
no angina pectoris n=7
no exercise test or
myocardial perfusion imaging
performed
n=15
history of myocardial infarction=1
coronary spasm n=2
diabetes mellitus n=2
left ventricular hypertrophy n=2
bridging n=1
cardiac syndrome X
VUmc criteria
n=18
positive exercise test or
ischaemia on SPECT
n=28
exercise test and/or
myocardal perfusion imaging
performed
n=45
patients with normal CAG
angina pectoris
no troponin release
n=60
patients with normal CAG
n=78
Patients underwent CAG
clinical data present
n=559
patients underwent CAG
year 2003
n=567
Fig. 2 Flowchart of the available information
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123the origins of this syndrome. Besides the use of a standard
and ﬁxed combination of inclusion criteria future studies
should apply a standard combination of exclusion criteria.
In a recent editorial, Camici proposed the following
exclusion criteria in order to obtain a more homogeneous
set of cardiac syndrome X patients: absence of left bundle
branch block; absence of even minimal irregularities on the
angiogram; no evidence of diabetes mellitus, arterial
hypertension, hyperlipidaemia, valve disease, epicardial
arterial spasm, and cardiomyopathy [7].
In our selection of CSX patients we decided to include
only patients with completely normal coronary angio-
grams, effort-induced angina pectoris, positive exercise
stress test and/or positive SPECT study. Furthermore, we
decided to add arrhythmias, left ventricular hypertrophy,
myocardial infarction in the medical history, and myocar-
dial bridging to the exclusion criteria proposed by Camici.
These inclusion and exclusion criteria resulted in an
attributable CSX incidence of only 3%.
Conclusions
The wide range of deﬁnitions of CSX in recent literature
and the variations in inclusion and exclusion criteria, par-
ticularly the latter, make interpretation of the results of
individual studies difﬁcult. This shows the need for a
generally accepted deﬁnition of CSX.
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